Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
Newton Charles W.	Director	2026-06-11	550 shares	$5K
Farzan Nima	Director	2026-06-04	3K shares	$28K
Knowles Julius	Director	2026-06-04	3K shares	$28K
Seth Alpna	Director	2026-06-04	3K shares	$28K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding KEROS THERAPEUTICS INC (KROS)?

Major stakeholders currently include BlackRock, Inc. ($26.6M), Nantahala Capital Management, LLC ($15.0M), Vanguard Capital Management LLC ($9.2M). Based on the latest 13F filings, there are a total of 151 tracked investment funds and institutions maintaining positions in KROS.

What is the overall institutional sentiment toward KROS recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $214.3M, driven by 72 managers accumulating shares while 94 reduced their exposure.

Which institutions have been selling or reducing their KROS positions?

In the latest period, 54 funds trimmed their holdings, and 40 managers completely exited their positions. The aggregate reported sell value was $254.8M.

Are there any notable investors adding KROS to their portfolios?

Yes, buying activity remains notable. 23 institutions opened new positions in {ticker}, and 49 existing holders added to their shares. The total reported buy value for the quarter amounted to $105.2M.